Teva (TEVA) Backed a Bid of Up to $125M in Cash Plus Assumed Liabilities for BioXcel’s Assets. Is Bankruptcy-Sale Risk Worth the At-Home Opportunity?
finance.yahoo.com
04.09.2026 18:01
48 views
Related stories
Tesla and SpaceX shares slide as Musk’s political push falls flat
marketwatch.com · 04.11
Treasury opens the door to changes in how it finances the growing U.S. debt. Here’s what you need to know.
marketwatch.com · 04.11
ADP says businesses add 86,000 jobs in October. Labor market shows small signs of improvement.
marketwatch.com · 04.11
The midterms have already cost Musk more than $60bn — and counting
ft.com · 04.11
Datadog’s stock extends steep declines in the wake of earnings
marketwatch.com · 04.11
Think the Fed will be done after two more rate hikes? How Friday’s jobs report may trigger a major market repricing.
marketwatch.com · 04.11